L'intérêt à découvert pour FMC donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de FMC. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

FMC (NYSE:FMC) Stock, Rapport sur les intérêts à découvert

FMC CORP

FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.

FMC Corp

FRMRS&MER BNCORP LODI CA by Farmers & Merchants Bancorp

Farmers & Merchants Bancorp

Federal Home Loan Mortgage Corp

Northern Lights Fund Trust IV FM Compounders Equity ETF

FRESENIUS MED CARE AG ORD by Fresenius Medical Care AG

Fresenius Medical Care AG

FM Focus Equity ETF

FORAN MINING CORP by Foran Mining Corporation

Foran Mining Corp

Tremisia&#xAE; fungicide receives registration in Ukraine, bringing growers a new tool to combat challenging crop diseases
 FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>), a leading global agricultural sciences company, today announced regulatory approval for Tremisia&#xAE; fungicide in Ukraine, marking the first introduction of the company's novel fluindapyr technology in the European, Middle East, and Africa (EMEA) region. The approval covers oilseed rape, sunflower, and wheat across more than 10 million hectares of Ukrainian farmland.
The Ukraine registration builds on FMC's successful commercialization of fluindapyr-based products in Argentina, Brazil, Mexico, Paraguay, South Korea, and the United States, with conditional approval secured in the Philippines earlier this year. Pending regulatory decisions, FMC anticipates launching fluindapyr-based products in Bolivia, Chile, Colombia, Honduras, and India, further expanding global access to this innovative fungicide technology.

News

FMC Gains Ukraine Approval For Tremisia Fungicide, Expands Footprint In EMEA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs lowered Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) price target from $48 to $46. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. Advance Auto Parts shares closed at $51.93 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/AAP/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim increased the price target for Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from $50 to $68. Guggenheim analyst Seamus Fernandez maintained a Buy rating. Cidara Therapeutics shares closed at $44.95 on Monday. <a href="https://www.benzinga.com/quote/CDTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) price target from $15 to $20. Needham analyst Serge Belanger maintained a Buy rating. CorMedix shares closed at $16.56 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/CRMD/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Lyell Immunopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) from $1 to $10. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Neutral rating. Lyell Immunopharma shares closed at $8.99 on Monday. <a href="https://www.benzinga.com/quote/LYEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $199 to $179. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. RH shares closed at $186.22 on Monday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut DICK&#8217;S Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) price target from $250 to $240. B of A Securities analyst Robert Ohmes maintained a Buy rating. DICK&#8217;S Sporting shares settled at $175.79 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised MACOM Technology Solutions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) price target from $250 to $270. B of A Securities analyst Vivek Arya maintained a Buy rating. MACOM Technology Solutions shares closed at $138.65 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) price target from $220 to $240. Keybanc analyst Steve Barger maintained an Overweight rating. Westinghouse Air Brake Technologies shares closed at $202.19 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from $200 to $220. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Applied Materials shares settled at $171.96 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald increased Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) price target from $90 to $115. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Lam Research shares closed at $91.61 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png" alt="" class="wp-image-959828" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Price Target

Markets

Analyst Ratings

Trading Ideas

AMAT

CDTX

CRMD

CTVA

LRCX

LYEL

MTSI

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Across the recent three months, 5 analysts have shared their insights on FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $46.8, a high estimate of $53.00, and a low estimate of $41.00. Observing a 5.41% increase, the current average has risen from the previous average price target of $44.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1750708865_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive FMC is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to FMC. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FMC compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for FMC's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of FMC's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FMC analyst ratings.</a>
<h2>Discovering FMC: A Closer Look</h2>
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
<h3>Financial Milestones: FMC's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: FMC's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -13.79%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: FMC's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -1.96%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): FMC's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.35% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): FMC's ROA stands out, surpassing industry averages. With an impressive ROA of -0.13%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: FMC's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.91, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess FMC: What You Need To Know

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>B of A Securities lowered Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) price target from $300 to $285. B of A Securities analyst Heather Balsky downgraded the stock from Buy to Neutral. Equifax shares closed at $255.70 on Friday. <a href="https://www.benzinga.com/quote/EFX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JMP Securities increased the price target for Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from $47 to $50. JMP Securities analyst Silvan Tuerkcan maintained a Market Outperform rating. Exelixis shares closed at $40.37 on Friday. <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc raised Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) price target from $230 to $245. Keybanc analyst Eric Gonzalez maintained an Overweight rating. Darden shares closed at $225.78 on Friday. <a href="https://www.benzinga.com/quote/DRI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital slashed the price target for Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from $29 to $22. BMO Capital analyst John McNulty downgraded the stock from Market Perform to Underperform. Dow shares closed at $27.76 on Friday. <a href="https://www.benzinga.com/quote/DOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) from $22 to $25. Baird analyst Rob Oliver downgraded the stock from Outperform to Neutral. Couchbase shares closed at $24.49 on Friday. <a href="https://www.benzinga.com/quote/BASE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) price target from $3 to $8. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. FMC shares settled at $41.07 on Friday. <a href="https://www.benzinga.com/quote/FMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) price target from $73 to $82. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Kroger shares closed at $71.97 on Friday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank increased Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) price target from $14 to $22. Deutsche Bank analyst David Begleiter maintained a Buy rating. Compass Minerals shares closed at $19.38 on Friday.  <a href="https://www.benzinga.com/quote/CMP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised the price target for Corteva, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) from $79 to $82. Wells Fargo analyst Richard Garchitorena maintained an Overweight rating. Corteva shares settled at $73.72 on Friday. <a href="https://www.benzinga.com/quote/CTVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Melius Research increased Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) price target from $110 to $175. Melius Research analyst Ben Reitzes upgraded the stock from Hold to Buy. AMD shares closed at $128.24 on Friday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/AMD/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="609" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334-1024x609.png" alt="" class="wp-image-958196" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334-1024x609.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334-768x457.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

BASE

EXEL

AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan analyst Anthony Paolone upgraded BXP, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) from Underweight to Neutral and raised the price target from $72 to $78. BXP shares closed at $71.47 on Friday. <a href="https://www.benzinga.com/quote/BXP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Michael Mueller upgraded the rating for Ventas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) from Neutral to Overweight and raised the price target from $70 to $72. Ventas shares closed at $62.45 on Friday. <a href="https://www.benzinga.com/quote/VTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Adrien de Saint Hilaire upgraded Omnicom Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) from Underperform to Neutral and maintained the price target of&nbsp;$80. Omnicom shares closed at $70.28 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Steve Powers upgraded The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) from Hold to Buy and raised the price target from $71 to $95. Estee Lauder shares closed at $75.20 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Richard Garchitorena upgraded the rating for FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) from Equal-Weight to Overweight and raised the price target from $41 to $50. FMC shares closed at $41.07 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying VTR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/VTR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23074421/image-333-1024x574.png" alt="" class="wp-image-957992" style="width:649px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23074421/image-333-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23074421/image-333-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23074421/image-333-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23074421/image-333.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

SEPN

This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Wells Fargo analyst Richard Garchitorena upgrades FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) from Equal-Weight to Overweight and raises the price target from $41 to $50.

Wells Fargo Upgrades FMC to Overweight, Raises Price Target to $50

General

FMC Corporation Partners With Corteva Agriscience To Expand FMC's Fluindapyr Fungicide Technology In The U.S. Corn And Soybean Markets

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the materials sector.
<h3 class="wp-block-heading">Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 8.55%</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Overweight rating and slashed the price target from $22 to $20 on May 5, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Wells Fargo analyst Michael Sison downgraded the stock from Overweight to Equal-Weight and lowered the price target from $17 to $13 on May 5, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: On May 28, Huntsman announced that it has completed the strategic review of its European Maleic Anhydride business.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0528">latest HUN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0528"><img loading="lazy" decoding="async" width="906" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070822/image-353.png" alt="" class="wp-image-929655" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070822/image-353.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070822/image-353-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070822/image-353-768x710.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 5.95%</li>
<li>Keybanc analyst Aleksey Yefremov maintained an Overweight rating and raised the price target from $49 to $53 on May 2, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Seaport Global analyst Michael Harrison maintained a Buy rating and cut the price target from $72 to $55 on March 5, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On April 30, FMC issued second-quarter adjusted EPS guidance below estimates.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest FMC <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0528">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0528"><img loading="lazy" decoding="async" width="920" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070859/image-354.png" alt="" class="wp-image-929656" style="width:604px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070859/image-354.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070859/image-354-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070859/image-354-768x707.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.30%</li>
<li>Morgan Stanley analyst Vincent Andrews maintained an Equal-Weight rating and cut the price target from $22 to $15 on May 12, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Mizuho analyst John Roberts upgraded the stock from Neutral to Outperform with a price target of $19 on March 27, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On May 6, Chemours reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0528">latest CC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0528"><img loading="lazy" decoding="async" width="908" height="815" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070926/image-355.png" alt="" class="wp-image-929658" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070926/image-355.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070926/image-355-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28070926/image-355-768x689.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock">Jim Cramer Says Rocket Is A &#8216;Very Fine&#8217; Company, Recommends Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Dividends

Wall Street's Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the materials sector.
<h3 class="wp-block-heading">Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 9.77%</li>
<li>BMO Capital analyst John McNulty downgraded the stock from Outperform to Market Perform and cut the price target from $13 to $7 on May 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Morgan Stanley analyst Vincent Andrews maintained an Equal-Weight rating and slashed the price target from $12 to $8 on May 5, 2024. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On April 30, Tronox Holdings posted first-quarter adjusted loss of 15 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest TROX <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="908" height="815" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09050938/image-100.png" alt="" class="wp-image-909780" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09050938/image-100.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09050938/image-100-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09050938/image-100-768x689.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 8.32%</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Overweight rating and cut the price target from $22 to $20 on May 5, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Wells Fargo analyst Michael Sison downgraded the stock from Overweight to Equal-Weight and slashed the price target from $17 to $13 on May 5, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 1, Huntsman reported in-line loss for the first quarter.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest HUN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="911" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09051009/image-101.png" alt="" class="wp-image-909782" style="width:559px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09051009/image-101.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09051009/image-101-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09051009/image-101-768x694.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.34%</li>
<li>Keybanc analyst Aleksey Yefremov maintained an Overweight rating and raised the price target from $49 to $53 on May 2, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Seaport Global analyst Michael Harrison maintained a Buy rating and cut the price target from $72 to $55 on March 5, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: On April 30, FMC issued second-quarter adjusted EPS guidance below estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest FMC <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="912" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09051041/image-102.png" alt="" class="wp-image-909783" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09051041/image-102.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09051041/image-102-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09051041/image-102-768x701.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

TROX

Wall Street's Most Accurate Analysts Give Their Take On 3 Materials Stocks With Over 6% Dividend Yields

Keybanc analyst Aleksey Yefremov maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Overweight and raises the price target from $49 to $53.

Keybanc Maintains Overweight on FMC, Raises Price Target to $53

Throughout the last three months, 12 analysts have evaluated FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $47.08, a high estimate of $55.00, and a low estimate of $38.00. This current average represents a 21.65% decrease from the previous average price target of $60.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1746133212_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of FMC's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Harrison</td>
<td>Seaport Global</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$48.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Joel Jackson</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$47.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to FMC. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FMC compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of FMC's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of FMC's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FMC analyst ratings.</a>
<h2>About FMC</h2>
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
<h3>FMC's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: FMC's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 6.82%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: FMC's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.37% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): FMC's ROE excels beyond industry benchmarks, reaching -0.37%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): FMC's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.78, FMC faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying FMC: Insights From 12 Analyst Reviews

WIIM

FMC shares are trading lower after the company issued Q2 adjusted EPS guidance below estimates.

UBS analyst Joshua Spector maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Neutral and raises the price target from $38 to $41.

UBS Maintains Neutral on FMC, Raises Price Target to $41

FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) affirms FY2025 Adj EPS guidance from $3.26-$3.70 to $3.26-$3.70 vs $3.41 analyst estimate. Affirms FY2025 sales outlook from $4.15 billion-$4.35 billion to $4.15 billion-$4.35 billion vs $4.19 billion estimate.

Guidance

FMC Affirms FY2025 Adj EPS Guidance of $3.26-$3.70 vs $3.41 Est; Affirms FY2025 Sales Guidance of $4.15B-$4.35B vs $4.19B Est

FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) is looking for Q2 Adj EPS of $0.52-$0.68 vs $0.75 analyst estimate. sees sales of $940.000 million-$1.100 billion vs $1.03 billion analyst estimate.

FMC Sees Q2 Adj EPS $0.52-$0.68 vs $0.75 Est; Sees Sales $940.000M-$1.100B vs $1.03B Est

FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.09 by 100 percent. This is a 50 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $791.40 million which beat the analyst consensus estimate of $784.05 million by 0.94 percent. This is a 13.79 percent decrease over sales of $918.00 million the same period last year.

Earnings

Earnings Beats

FMC Q1 Adj. EPS $0.18 Beats $0.09 Estimate, Sales $791.40M Beat $784.05M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Wells Fargo analyst Richard Garchitorena maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Equal-Weight and lowers the price target from $43 to $41.

Wells Fargo Maintains Equal-Weight on FMC, Lowers Price Target to $41

Peru approves Keenali&#x2122; herbicide, transforming rice weed management in high-growth Latin American market&nbsp;
FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>), a leading global agricultural sciences company, today announced it has received regulatory approval for Keenali&#x2122; herbicide powered by Dodhylex&#x2122; active (tetflupyrolimet) in Peru. The approval represents the first active ingredient and commercial product registration globally for this breakthrough herbicide technology. Dodhylex&#x2122; active is the first and only herbicide classified by the Herbicide Resistance Action Committee (HRAC) and the Weed Science Society of America (WSSA) as a Group 28 herbicide.

FMC Gets Regulatory Approval For Keenali Herbicide Powered By Dodhylex Active In Peru

In the preceding three months, 12 analysts have released ratings for FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for FMC, revealing an average target of $50.75, a high estimate of $65.00, and a low estimate of $38.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 20.25%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744668042_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of FMC by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Aleksey Yefremov &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $49.00&#x7C;$51.00 &#x7C; 
&#x7C;Duffy Fischer &#x7C;Goldman Sachs &#x7C;Announces &#x7C;Buy &#x7C; $51.00&#x7C;- &#x7C; 
&#x7C;Michael Harrison &#x7C;Seaport Global &#x7C;Lowers &#x7C;Buy &#x7C; $55.00&#x7C;$72.00 &#x7C; 
&#x7C;Aleksey Yefremov &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $51.00&#x7C;$55.00 &#x7C; 
&#x7C;Benjamin Theurer &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $48.00&#x7C;$65.00 &#x7C; 
&#x7C;Joshua Spector &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $38.00&#x7C;$66.00 &#x7C; 
&#x7C;Steve Byrne &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $48.00&#x7C;$61.00 &#x7C; 
&#x7C;Joel Jackson &#x7C;BMO Capital &#x7C;Lowers &#x7C;Market Perform &#x7C; $50.00&#x7C;$62.00 &#x7C; 
&#x7C;Vincent Andrews &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $46.00&#x7C;$70.00 &#x7C; 
&#x7C;Arun Viswanathan &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $47.00&#x7C;$78.00 &#x7C; 
&#x7C;Patrick Cunningham &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $61.00&#x7C;$55.00 &#x7C; 
&#x7C;Benjamin Theurer &#x7C;Barclays &#x7C;Maintains &#x7C;Overweight &#x7C; $65.00&#x7C;$65.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to FMC. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FMC compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of FMC's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into FMC's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FMC analyst ratings.</a>
<h2>Delving into FMC's Background</h2>
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
<h3>FMC's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: FMC's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 6.82%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): FMC's ROE stands out, surpassing industry averages. With an impressive ROE of -0.37%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): FMC's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.78, FMC faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Have This To Say About FMC

Commodities

Press Releases

FMC Corporation Declares Quarterly Dividend

FMC Corporation delivers first quarter results at higher end of guidance range, reaffirms full-year outlook

FMC Corporation demonstrates climate-smart, business-forward approach to sustainability

Kuehn Law Encourages Investors of FMC Corporation to Contact Law Firm

FMC Corporation and Corteva Agriscience collaborate to provide fluindapyr fungicide technology to more U.S. growers

FMC ALERT: Bragar Eagel & Squire, P.C. is Investigating FMC Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

FMC Corporation announces date for second quarter 2025 earnings release and webcast conference call

Legal

Johnson Fistel, PLLP Investigates Constellation Brands, Atkore, Dick's Sporting Goods, and FMC Corporation on Behalf of Long-term Shareholders

FMC Corporation expands novel fluindapyr fungicide technology to EMEA region

ATKR

American Vanguard Corporation Common Stock ($0.10 Par Value)

American Vanguard

Bioceres Crop Solutions Corp. - Ordinary Shares

Bioceres Crop Solutions

CF Industries Holdings, Inc. Common Stock

CF Industries Holdings

Corteva

Enlightify

Brazil Potash

Intrepid Potash

Mosaic

N2OFF

Scotts Miracle-Gro Company (The) Common Stock

Scotts Miracle Gro

CVR Partners, LP Common Units representing Limited Partner Interests

CVR Partners

Wells Fargo

Keybanc

Goldman Sachs

Seaport Global

Comments

FMC

Intérêt court

FMC (NYSE:FMC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL